Contentious MS therapy about to be tested
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 19/04/2012 (5247 days ago), so information in it may no longer be current.
CANADA’S Health Minister Leona Aglukkaq announced Wednesday the federal government will fund a clinical trial for “liberation treatment,” an experimental vein therapy for multiple sclerosis developed by an Italian doctor.
The MS Society of Canada, a co-funding partner of the project, said it’s “thrilled” by the announcement that may bring “definitive answers” about the controversial treatment developed by Dr. Paolo Zamboni.
The clinical trial for chronic cerebrospinal cenous cnsufficiency in Canadians with multiple sclerosis seeks to determine the safety of venous angioplasty, also known as “liberation treatment” which requires the opening of blocked veins, the Canadian Institutes for Health Research said in a release about the announcement.
Liberation treatment rejects long-held medical opinion that MS is an autoimmune disease. At least two Canadians have reportedly died overseas from complications of the procedure, which is currently unavailable in Canada.
Asked about the controversy surrounding the procedure, MS Society of Canada CEO Yves Savoie said he supports the call of those concerned about the treatment for more rigorous research.
The trial is subject to an ethics approval in Canada in “a way that balances our hunger for innovation and research with respect for dignity of human life,” Savoie said.
The government is withholding the names of the researchers and institutions involved in the project “to protect the independence” of the ethics review, according to CIHR, which launched a call for research applications to select the team of researchers.
Canada has among the highest MS rates in the world. There is no known cure, but symptoms may be managed.
— Postmedia News